Description
BML-277 is an arylbenzimidazole inhibitor of checkpoint kinase (CHK) 2. This compound displays cytoprotective activity, protecting CD4+ and CD8+ T cells against radiation-induced apoptosis.
Product Unit Size | Cost | Quantity | Stock |
---|
BML-277 is an arylbenzimidazole inhibitor of checkpoint kinase (CHK) 2. This compound displays cytoprotective activity, protecting CD4+ and CD8+ T cells against radiation-induced apoptosis.
Cas No. | 516480-79-8 |
---|---|
Purity | ≥98% |
Formula | C20H14ClN3O2 |
Formula Wt. | 363.80 |
Chemical Name | 2-[4-(4-Chlorophenoxy)phenyl]-1H-benzimidazole-5-carboxamide |
IUPAC Name | 2-[4-(4-Chlorophenoxy)phenyl]-1H-benzimidazole-5-carboxamide |
Solubility | DMSO 72 mg/mL Ethanol 21 mg/mL Water Insoluble |
Store Temp | -20°C |
---|---|
Ship Temp | Ambient |
MSDS | |
---|---|
Info Sheet |
Arienti KL, Brunmark A, Axe FU, et al. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem. 2005 Mar 24;48(6):1873-85. PMID: 15771432.